1. Introduction {#sec1-molecules-21-01167}
===============

*Aphanamixis polystachya* (Wall.) R.N. Parker (Meliaceae) is a tropical neem tree native to Asia, especially China and India. According to previous studies, the meliaceaeous plants are famous for the limonoid-producing source and the pest control function in agriculture \[[@B1-molecules-21-01167],[@B2-molecules-21-01167]\]. Phytochemical investigations of this plant have resulted in isolation of many limonoids with diverse skeletons \[[@B3-molecules-21-01167],[@B4-molecules-21-01167],[@B5-molecules-21-01167],[@B6-molecules-21-01167],[@B7-molecules-21-01167]\]. Other structures such as guaiane sesquiterpenes from the seeds \[[@B8-molecules-21-01167]\], lignans from the stem barks \[[@B9-molecules-21-01167]\], chromone, and flavonoid glycosides from the roots \[[@B10-molecules-21-01167]\] were also reported. In biological studies, it has been used as traditional Bangladesh medicine for the treatment of cancers, diabetes, and liver diseases \[[@B11-molecules-21-01167]\] in addition to insecticide applications. Besides, the leaf extract showed CNS (central nervous system) depressant and analgesic activity in vivo \[[@B12-molecules-21-01167]\], as well as antimicrobial, antioxidant, cytotoxic, and thrombolytic activities in vitro \[[@B13-molecules-21-01167]\]. Currently, some limonoids from *A. polystachya* attract much attention due to their interesting anticancer \[[@B14-molecules-21-01167]\], antifungal \[[@B15-molecules-21-01167]\], and antifeedant activities \[[@B16-molecules-21-01167],[@B17-molecules-21-01167]\].

Continuing our phytochemical investigation on the new anti-cancer and anti-inflammatory agents from terrestrial source, the crude extract from the roots of *A. polystachya* showed significant inhibition on superoxide anion generation and elastase release by human neutrophils in response to FMLP/CB at 10 μg/mL. Fractionation of the active components from the roots of this species was thus initiated. Herein, we report the isolation and structural elucidation of four new and six known triterpenoids, together with one known steroid from the roots of *A. polystachya*. The evaluation against human tumor cell lines and inhibitory activities on superoxide anion generation and elastase release are also discussed.

2. Materials and Methods {#sec2-molecules-21-01167}
========================

2.1. General Experimental Procedures {#sec2dot1-molecules-21-01167}
------------------------------------

Optical rotations were recorded on a JASCO DIP-1000 polarimeter (JASCO, Tokyo, Japan). IR spectra were taken on a HORIBA FT-720 spectrophotometer (HORIBA, Kyoto, Japan). The ^1^H- and ^13^C-NMR spectra as well as 2D NMR spectra (COSY, HMQC, HMBC, and NOESY) were recorded in CDCl~3~ on a Bruker AVX NMR spectrometer (Bruker, Karlsruhe, Germany) operating at 400 MHz for ^1^H and 100 MHz for ^13^C using the CDCl~3~ solvent peak as internal standard (δ~H~ 7.265, δ~C~ 77.0 ppm). Low-resolution ESIMS were recorded on a VG Quattro 5022 mass spectrometer (VG Instruments, Altrincham, UK). HRESIMS were measured on a JEOL HX 110 mass spectrometer (JEOL, Peabody, MA, USA). LiChrospher^®^ Si 60 (5 μm, 250-10, Merck, Darmstadt, Germany) and LiChrospher^®^ 100 RP-18e (5 μm, 250-10, Merck) were used for NP-HPLC and RP-HPLC (Hitachi, L-6250, Kyoto, Japan; flow rate 2 mL/min, UV detection at 254 nm), respectively. HepG 2, A549 and MCF-7 cancer cells were purchased from Bioresource Collection and Research Center, Food Industry Research and Development Institute (Hsinchu, Taiwan), and Hep-2 was purchased from ATCC (American Type Culture Collectio, Manassas, VA, USA).

2.2. Plant Material {#sec2dot2-molecules-21-01167}
-------------------

The roots of *Aphanamixis polystachya* (Wall.) R.N. Parker were collected in Ping-Tong County, Taiwan, in April 2012. The plant material was identified by one of the authors (C.T.C.). A voucher specimen (code No. TP 98-1) has been deposited at the School of Pharmacy, National Taiwan University, Taipei, Taiwan.

2.3. Extraction and Isolation {#sec2dot3-molecules-21-01167}
-----------------------------

The air-dried roots (6.6 kg) of *A. polystachya* were ground and extracted thrice with acetone at room temperature and concentrated under reduced pressure to obtain a crude extract (250 g). The extract was partitioned between EtOAc:H~2~O (1:1) to give an EtOAc-soluble layer. After evaporating the organic solvent, the EtOAc residue (90 g) was partitioned between *n*-hexane:MeOH:H~2~O (4:3:1) to afford a MeOH/H~2~O extract. The MeOH/H~2~O extract (60 g) was subjected to pass over a Sephadex LH-20 column eluted with MeOH to afford fractions A--F. Fraction C (38 g) was separated on a Si gel (63--200 μm, 90 × 120 mm) column (*n*-hexane:EtOAc:MeOH, 100:0:0 to 0:0:100, 1 L for each gradient solvent) to afford fraction C-14 (7.1 g), which was further chromatographed on Si gel (\<63 μm, 65 × 600 mm) column (*n*-hexane:EtOAc, 1:1, 5 L) to furnish three fractions, C-14-C, C-14-D, and C-14-E. Fraction C-14-C (1.7 g) was separated with a Si gel column and eluted with *n*-hexane:EtOAc:CH~2~Cl~2~ (1:1:1, 2.5 L) to give three subfractions, C-14-C-4, C-14-C-5 and C-14-C-6. Subfraction C-14-C-4 (385 mg) was subjected to RP-HPLC (5 μm, 10 mm × 250 mm) (MeOH:H~2~O, 7:1) to give **1** (7.6 mg, Rt = 20.3 min) and **2** (11.5 mg, Rt = 16.4 min). Subfraction C-14-C-6 (802 mg) was washed with MeOH and filtrated to yield **10** (443 mg). Fraction C-14-D (1.8 g) was separated by a reverse-phase column (20--50 μm, 35 × 35 mm) and eluted with MeOH/H~2~O (7:3, 2 L) to afford ten subfractions, C-14-D-1 to C-14-D-10. Subfraction C-14-D-6 (174 mg) was separated with an RP-HPLC (CH~3~CN/H~2~O, 55:45) to yield methyl-1ξ,7*R*-diacetoxy-23*R*,25-dihydroxy-20*S*,24*R*-21,24-epoxy-3,4-*seco*-apotirucall-4(28),14(15)-diene-3-oate (**5**, 15.6 mg, Rt = 35.4 min). Separation of fraction C-14-E (1.1 g) by a Si gel (\<63 μm, 35 cm × 30 mm) column (*n*-hexane--acetone, 2:1, 2 L) obtained three subfractions, C-14-E-3, C-14-E-4 and C-14-E-6. Subfraction C-14-E-3 (236 mg) was applied on an RP-HPLC (CH~3~CN--H~2~O, 3:2) to yield **3** (18.1 mg, Rt = 39.1 min) and 2β,3β-dihydroxy-5α-pragnan-16-one (**11**, 17.8 mg, Rt = 22.2 min). Subfraction C-14-E-4 (187 mg) was purified by reverse-phase HPLC (MeOH--H~2~O, 7:1) to obtain **4** (26 mg, Rt = 11.1 min). Subfraction C-14-E-6 (358 mg) was separated by RP-HPLC (MeOH:H~2~O, 3:2) to furnish rohituka 3 (**6**, 30.7 mg, Rt = 37.7 min), rohituka 7 (**7**, 20.8 mg, Rt = 33.6 min), nymania 1 (**8**, 19.8 mg, Rt = 55.8 min), and rubrin G (**9**, 11.5 mg, Rt = 76.7 min).

3. Spectral Data {#sec3-molecules-21-01167}
================

*Aphataiwanin A (***1***)*. Colorless amorphous solid; $\left\lbrack \alpha \right\rbrack_{D}^{25}$ −60 (*c* 0.1, MeOH); IR (CH~2~Cl~2~) *v*~max~ 3479, 3078, 1740, 1645, 977, 900 cm^−1^; ^1^H-NMR (CDCl~3~) and ^13^C-NMR (CDCl~3~) spectroscopic data, see [Table 1](#molecules-21-01167-t001){ref-type="table"} and [Table 2](#molecules-21-01167-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 653.3684 \[M + Na\]^+^ (calcd for C~36~H~54~O~9~Na, 653.3660).

*Aphataiwanin B (***2***)*. Colorless amorphous solid; $\left\lbrack \alpha \right\rbrack_{D}^{25}$ −90 (*c* 0.1, MeOH); IR (CH~2~Cl~2~) *v*~max~ 3484, 3071, 1740, 1643, 983, 902 cm^−1^; ^1^H-NMR (CDCl~3~) and ^13^C-NMR (CDCl~3~) spectroscopic data, see [Table 1](#molecules-21-01167-t001){ref-type="table"} and [Table 2](#molecules-21-01167-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 653.3681 \[M + Na\]^+^ (calcd for C~36~H~54~O~9~Na, 653.3660).

*Aphataiwanin C (***3***)*. Colorless amorphous solid; $\left\lbrack \alpha \right\rbrack_{D}^{25}$ −60 (*c* 0.1, MeOH); IR (CH~2~Cl~2~) *v*~max~ 3510, 2930, 1740, 1650, 972, 900 cm^−1^; ^1^H-NMR (CDCl~3~) and ^13^C-NMR (CDCl~3~) spectroscopic data, see [Table 1](#molecules-21-01167-t001){ref-type="table"} and [Table 2](#molecules-21-01167-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 671.3785 \[M + Na\]^+^ (calcd for C~36~H~56~O~10~Na, 671.3765).

*Aphataiwanin D (***4***)*. Colorless amorphous solid; $\left\lbrack \alpha \right\rbrack_{D}^{25}$ −170 (*c* 0.1, MeOH); IR (CH~2~Cl~2~) *v*~max~ 3491, 2932, 1741, 1642, 900 cm^−1^; ^1^H-NMR (CDCl~3~) and ^13^C-NMR (CDCl~3~) spectroscopic data, see [Table 1](#molecules-21-01167-t001){ref-type="table"} and [Table 2](#molecules-21-01167-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 671.3763 \[M + Na\]^+^ (calcd for C~36~H~56~O~10~Na, 671.3765).

4. Biological Activities {#sec4-molecules-21-01167}
========================

4.1. Cytotoxicity Assay {#sec4dot1-molecules-21-01167}
-----------------------

Cytotoxicity was tested against human Hep-G2 (hepatocellular carcinoma), HEp-2 (laryngeal carcinoma), A549 (lung carcinoma) and MCF-7 (breast adenocarcinoma) tumor cell lines. The assay procedure using MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) was carried out as previously described \[[@B18-molecules-21-01167],[@B19-molecules-21-01167]\]. The cells were cultured in RPMI-1640 medium. After seeding of cells in a 96-well microplate for 4 h, 20 μL of sample was placed in each well and incubated at 37 °C for 3 days, and then 20 μL MTT was added for 5 h. After removing the medium and putting DMSO (200 μL/well) into the microplate with shaking for 10 min, the formazan crystals were redissolved and their absorbance was measured on a microtiter plate reader (MR 7000, Dynatech, Missouri City, TX, USA) at a wavelength of 550 nm. Mitomycin C was used as a positive control.

4.2. Anti-Inflammatory Assays, Inhibitory Effect on Superoxide Anion Generation and Elastase Release by Human Neutrophils {#sec4dot2-molecules-21-01167}
-------------------------------------------------------------------------------------------------------------------------

Neutrophils were obtained by means of dextran sedimentation and Ficoll centrifugation. Superoxide generation and elastase release were carried out according to a procedure described previously \[[@B20-molecules-21-01167]\]. Superoxide anion production was assayed by monitoring the superoxide dismutase-inhibitable reduction of ferricytochrome *c.* Elastase release experiments were performed using MeO-Suc-Ala-Ala-Pro-Valp-nitroanilide as the elastase substrate. Genistein was used as a standard compound, which showed inhibition of 65.0 ± 5.7 and 51.6 ± 5.9 at 10 μg/mL, respectively, on superoxide anion generation and elastase release.

5. Results and Discussion {#sec5-molecules-21-01167}
=========================

Sephadex LH-20 and extensive column chromatography furnished four new apotirucallane-type triterpenoids **1**--**4** ([Figure 1](#molecules-21-01167-f001){ref-type="fig"}), together with a protolimonoid, methyl-1ξ,7*R*-diacetoxy-23*R*,25-dihydroxy-20*S*,24*R*-21,24-epoxy-3,4-*seco*-apotirucall-4(28),14(15)-diene-3-oate (**5**) \[[@B21-molecules-21-01167]\]; five limonoids, rohituka 3 (**6**) \[[@B22-molecules-21-01167]\], rohituka 7 (**7**) \[[@B22-molecules-21-01167]\], nymania 1 (**8**) \[[@B23-molecules-21-01167]\], rubrin G (**9**) \[[@B24-molecules-21-01167]\], prieurianin (**10**) \[[@B25-molecules-21-01167],[@B26-molecules-21-01167]\]; and one steroid, 2β,3β-dihydroxy-5α-pragnan-16-one (**11**) \[[@B27-molecules-21-01167],[@B28-molecules-21-01167]\]. The structures of the new compounds were established by interpretation of their spectroscopic data, especially 2D NMR. The relative configurations of compounds **1**--**4** were determined by NOESY and comparison of NMR data with those published in reference papers.

Compound **1**, $\left\lbrack \alpha \right\rbrack_{D}^{25}$ −60 (MeOH), had the molecular formula of C~36~H~54~O~9~ and 10 degrees of unsaturation, as deduced from the HRESIMS (*m/z* 653.3684 \[M + Na\]^+^) and ^13^C-NMR/DEPT spectra. The IR absorption bands revealed the presence of hydroxy (3479 cm^−1^), ester (1740 cm^−1^), and double bond (1645 cm^−1^) functionalities in **1**. The ^1^H-NMR data of **1** ([Table 1](#molecules-21-01167-t001){ref-type="table"}) exhibited seven methyl singlets (δ~H~ 0.96, 1.00, 1.14, 1.78, 1.79, 1.96 and 2.04), two methoxy singlets (δ~H~ 3.39, 3.66), exomethylene (δ~H~ 4.85, 4.93, 5.02 and 5.05), an olefinic methine doublet (δ~H~ 5.27, *J* = 3.0 Hz), and five oxygen-bearing methine signals (δ~H~ 3.83, 4.23, 4.78, 5.16 and 5.49). The ^13^C-NMR ([Table 2](#molecules-21-01167-t002){ref-type="table"}) and DEPT spectra of **1** showed 36 carbon signals, consisting of three ester carbonyls (δ~C~ 170.2, 170.5, and 172.0), two olefinic methylenes (δ~C~ 112.8, 116.6), an olefinic methine (δ~C~ 119.1), three olefinic quaternary carbons (δ~C~ 144.9, 145.1, and 159.2), five oxymethines (δ~C~ 74.7, 77.2, 78.1, 80.7 and 104.6), four aliphatic methines (δ~C~ 34.5, 44.3, 45.8, and 52.9), six aliphatic methylenes (δ~C~ 18.5, 29.3, 31.0, 33.5, 35.2, and 35.5), two methoxyls (δ~C~ 52.3, 54.9), and seven methyls (δ~C~ 15.2, 18.7, 20.8, 21.2, 21.5, 23.0, and 26.9). This accounted for 6 of the 10 degrees of unsaturation, indicating that **1** is a tetracyclic triterpenoid with two acetyl and two methoxyl moieties.

The COSY spectrum ([Figure 2](#molecules-21-01167-f002){ref-type="fig"}) of **1** exhibited four proton spin systems of H-1 (δ~H~ 5.49)/H~2~-2 (δ~H~ 2.47, 2.81) and H-5 (δ~H~ 2.44)/H~2~-6 (δ~H~ 1.63, 2.14)/H-7 (δ~H~ 5.16); H-9 (δ~H~ 2.18)/H~2~-11 (δ~H~ 1.67, and 1.89)/H~2~-12 (δ~H~ 1.54, and 1.65); and a proton sequence between H-15 (δ~H~ 5.27)/H~2~-16 (δ~H~ 1.93, 2.10)/H-17 (δ~H~ 1.92)/H-20 (δ~H~ 2.21)/H-21 (δ~H~ 4.78) and between H-20/H~2~-22 (δ~H~ 1.70, 1.87)/H-23 (δ~H~ 4.23) /H-24 (δ~H~ 3.83). In the HMBC spectrum ([Figure 2](#molecules-21-01167-f002){ref-type="fig"}), the H~3~-19 signal showed correlations to C-1 (δ~C~ 77.2), C-5 (δ~C~ 44.3), C-9 (δ~C~ 34.5) and C-10 (δ~C~ 44.3), and the H~2~-29 had correlations with C-4 (δ~C~ 145.1), C-5 and C-28 (δ~C~ 23.0) suggesting the ring B. In addition, the HMBC correlations of H~3~-18 (δ~H~ 1.00) with C-13 (δ~C~ 46.3), C-12 (δ~C~ 33.5), C-14 (δ~C~ 159.2), C-17 (δ~C~ 52.9), and of H~3~-30 (δ~H~ 1.14) with C-7 (δ~C~ 74.7), C-8 (δ~C~ 42.5), C-9 (δ~C~ 34.5) and C-14 (δ~C~ 159.2) established rings C and D. Moreover, the HMBC correlations of both H~3~-26 (δ~H~ 1.78) and H~2~-27 (δ~H~ 4.93, 5.05) with C-24 (δ~C~ 78.1) and C-25 (δ~C~ 144.9) indicated a methyl vinyl group to be attached at the oxygenated C-24. The HMBC correlations of the methoxy protons (δ~C~ 3.39) with C-21 (δ~C~ 104.6) and of H-21 (δ~H~ 4.78) with C-23 (δ~C~ 80.7) revealed the tetrahydrofuran ring with a methoxy group at C-21. The remaining methoxy (δ~H~ 3.36) group was found to be connected with C-3 (δ~C~ 172.0), and the H-1 (δ~H~ 5.49) and H-7 (δ~H~ 5.16) were connected with the acetyl carbonyl carbons (δ~C~ 170.5, 170.2) indicated that the acetyl groups were attached at C-1 and C-7, respectively. This 2D NMR spectroscopic analysis was used to identify **1** as an A-seco apo-tirucallane triterpenoid \[[@B15-molecules-21-01167]\].

The relative configuration of **1** was determined by the analysis of NOESY correlations ([Figure 3](#molecules-21-01167-f003){ref-type="fig"}). Assuming that H-5 of **1** was α-oriented similar to that of the A-seco apotirucallane tetranortriterpenes \[[@B15-molecules-21-01167],[@B29-molecules-21-01167]\], the NOESY correlations between H-6α/H-5/H-9/H~3~-18/H-16α revealed that these protons were on the \#x3B1;-face. The NOESY correlations of H~3~-19 with H-1, H-6β and H-11β, as well as Me-30 with H-7 indicating these protons were on the β-face. In addition, NOESY correlations of H-20/H-21/H-22α/H-23 suggested that these protons were all in α-face and the C-21 methoxy was β-oriented. On comparing the ^1^H- and ^13^C-NMR spectra of **1** with those of chisopanin C \[[@B30-molecules-21-01167]\] and polystanins C and D \[[@B31-molecules-21-01167]\], it was noted that the configurations of C-20, C-21 and C-23 were assigned *S*, *S* and *R*, respectively, the same as those of polystanin D \[[@B31-molecules-21-01167]\], and the hydroxy at C-24 was assigned as α-disposition, the same as that of chisopanin C \[[@B30-molecules-21-01167]\]. Therefore, structure **1** was established and a name aphataiwanin A was given.

Compound **2**, $\left\lbrack \alpha \right\rbrack_{D}^{25}$ −90 (MeOH), had the same molecular formula C~36~H~54~O~9~ as **1**, as deduced from HRESIMS (*m/z* 653.3681 \[M + Na\]^+^) and DEPT spectra. The IR absorption bands revealed the presence of OH (3484 cm^−1^), ester (1740 cm^−1^) and double bond (1643 cm^−1^) in **2**. The 1D and 2D NMR spectra of **2** were similar to those of **1**, suggesting that **2** was an analogue of **1**. On comparing the ^13^C-NMR spectra of **1** and **2**, it was found that the C-21 and C-17 chemical shifts of **2** (δc 109.3, 58.1) were downfield compared to the same carbons of **1** (δ 104.6, 52.9). Thus it was suggested that the configuration of the C-21 methoxy group in **2** was different from that in **1**. Also, both the COSY and HMBC correlations showed that all structural fragments were similar to those of **1**, confirming that compound **2** is an epimer of **1**, in which the C-21 methoxy was α-oriented.

The relative configuration of **2** was determined by NOESY experiment, in which the H~3~-19 and H~3~-30 were assigned to be β-oriented while H~3~-18, H-9, and H-5 were α-orientation. NOESY correlations between H-21/H-22β and H-20/H-23, and H-23/H-22β indicated that the methoxy group was α-oriented. Comparing the ^13^C-NMR data with those of chisopanin C \[[@B30-molecules-21-01167]\] assigned the configuration of C-13, C-17, C-20, C-23 and C-24 as *S*, *S*, *S*, *R*, *R* and *R*, respectively. Therefore, the structure of compound **2** was determined and it was named aphataiwanin B.

Compound **3**, $\left\lbrack \alpha \right\rbrack_{D}^{25}$ −60 (MeOH), was obtained as an amorphous solid and found to possess the molecular formula C~36~H~56~O~10~, (one more oxygen atom than **1**) as inferred from its HRESIMS (*m/z* 671.3785 \[M + Na\]^+^). The similar ^1^H- and ^13^C-NMR spectroscopic data of **3** and **1** suggested that they are close analogues. However, the ^1^H-NMR spectrum of **3** exhibited eight methyl singlets (δ~H~ 0.95, 1.00, 1.14, 1.26, 1.27, 1.78, 1.96 and 2.04) instead of seven in **1** and only three olefinic protons (δ~H~ 4.84, 5.02 and 5.27) instead of five in **1**, implying that a double bond was missing in **3**. In the ^13^C-NMR spectrum, compound **3** was found possessing an additional methyl (δ~C~ 26.5) and lacking an olefinic methylene, in comparison to **1**. The additional methyl group was assigned at C-27 by observation of the HMBC correlations from H~3~-27 (δ~H~ 1.26) and H~3~-26 (δ~H~ 1.27) to C-25 (δ~C~ 73.1) and C-24 (δ~C~ 76.8). The relative configuration of **3** was determined on the basis of the NOESY experiment and comparing the *J* values of **3** with those of **1**. The result was identical to **1**, suggesting the same configuration. On the basis of above interpretations, the structure of **3** was categorized into the group of ring A-seco apotirucallol and a name aphataiwanin C was given.

Compound **4** was isolated as an amorphous solid, $\left\lbrack \alpha \right\rbrack_{D}^{25}$ −170 (MeOH). It had the same molecular formula C~36~H~56~O~10~ as **3**, as derived from HRESIMS at *m/z* 671.3763 (\[M + Na\]^+^). The IR spectrum revealed that **4** contained a hydroxyl (3491 cm^−1^), ester (1741 cm^−1^), and double bond (1642 cm^−1^) functionalities. The ^1^H- and ^13^C-NMR spectra of **4** ([Table 1](#molecules-21-01167-t001){ref-type="table"} and [Table 2](#molecules-21-01167-t002){ref-type="table"}) were similar to those of **3** except for the hemiacetal carbon shifted downfield to δ~C~ 109.7 (C-21) in **3** and the oxygenated carbon C-23 shifted upfield to δ~C~ 76.9. The ^1^H-^1^H COSY and HMBC of **4** revealed cross peaks similar to those of **3**, suggesting that compound **4** was an epimer of **3**. The configuration at C-21 was determined by NOESY experiment. NOESY correlations between H-21/H-22β, H-20/H-22α and H-22α/H-23 indicated that the methoxy group was α-oriented. Other NOESY correlations were the same as those of **3**. Thus, the structure of compound **4** was elucidated and the name aphataiwanin D was given.

The 11 isolates were evaluated for their cytotoxic activities against human hepatocellular carcinoma (Hep-G2), lung carcinoma (A549), epithelial type 2 (HEp-2), and breast adenocarcinoma (MCF-7) cell lines in vitro. Among these compounds, **5** possessed significant activity (ED~50~ value of 6.83 ± 0.63 μg/mL) against MCF-7 cells and mild activity against Hep-G2 and A549 cells (ED~50~ value of 11.38 ± 0.98 and 15.49 ± 0.76 μg/mL). Simultaneously, compounds **1** and **10** also showed mild activities against Hep-G2 and HEp-2, respectively, with IC~50~ values of 16--17 μg/mL ([Table 3](#molecules-21-01167-t003){ref-type="table"}). In terms of anti-inflammation, compounds **1**--**11** were tested on superoxide anion generation and elastase release by human neutrophils in the presence of FMLP/CB ([Table 4](#molecules-21-01167-t004){ref-type="table"}). Only compounds **4** and **5** showed significant anti-inflammatory activity, as tested on superoxide anion generation with IC~50~ at 5.79 ± 0.88 and 1.25 ± 0.17 μg/mL, as well as the significant inhibition on elastase release with IC~50~ at 5.22 ± 0.24 and 2.26 ± 0.05 μg/mL, respectively.

6. Conclusions {#sec6-molecules-21-01167}
==============

In the present study, 10 tetranortriterpenoids, including four new compounds and a steroid, were isolated; compounds **1**--**5** belong to a group of protolimonoids, ring A-seco apotirucallol, while **6**--**10** can be classified as rings A,B-seco prieurianins. Among these secondary metabolites, liaphataiwanins A (**1**) and D (**4**), **5**, and prieurianin (**10**) were found to have mild cytotoxicities against cancer cells and moderate to potent anti-inflammatory activities. Compound **5**, which has the moiety of six-member ether ring, showed the best biological function. The chemical constituents and the evaluation of cytotoxicities against human cancer cells and anti-inflammatory activities reported herein may provide beneficial information for further phytotherapy research.
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molecules-21-01167-t001_Table 1

###### 

^1^H-NMR spectroscopic data (400 MHz) of compounds **1**--**4** ^a^.

  Position    1                           2                           3                      4
  ----------- --------------------------- --------------------------- ---------------------- ---------------------------
  1           5.49 d (10.8)               5.49 d (10.8)               5.49 d (10.8)          5.48 d (10.8)
  2α          2.47 dd (13.8, 10.8)        2.46 dd (13.8, 10.8)        2.46 dd (13.8, 10.8)   2.46 dd (13.8, 10.8)
  2β          2.81 d (13.8)               2.81 d (13.8)               2.81 d (13.8)          2.81 d (13.8)
  5           2.44 d (3.0)                2.45 d (3.0)                2.44 overlap           2.44 d (3.6)
  6*α*        1.63 dt (14.4, 3.0)         1.62 dt (14.4, 3.0)         1.63 d (13.8)          1.63 dd (13.8, 3.6)
  6β          2.14 d (14.4)               2.14 d (14.4)               2.14 d (13.8)          2.15 d (13.8)
  7           5.16 s                      5.15 s                      5.15 s                 5.14 s
  9           2.18 m                      2.20 dd (12.0, 6.6)         2.19 dd (12.0, 6.6)    2.19 dd (12.0, 6.6)
  11α         1.89 m                      1.92 dd (12.0, 3.0)         1.94 d (12.0)          1.90 overlap
  11β         1.67 m                      1.66 m                      1.70 m                 1.67 dd (15.0, 12.0)
  12α         1.65 m                      1.86 dd (10.2, 3.0)         1.66 d (13.2)          1.81 dd (10.8, 9.0)
  12β         1.54 dt (13.2, 9.6)         1.48 d (10.2)               1.55 dd (13.2, 9.6)    1.46 dd (10.8, 8.4)
  15          5.27 d (3.0)                5.25 d (2.4)                5.27 d (2.4)           5.25 s
  16α         1.93 dd (13.8, 7.8)         1.93 overlap                1.99 d (11.4)          1.92 d (15.6)
  16β         2.10 ddd (13.8, 7.8, 3.0)   2.1 ddd (15.6, 7.2, 3.6)    2.10 m                 2.08 dd (15.6, 7.8)
  17          1.92 m                      1.70 dd (7.2, 3.6)          1.97 m                 1.71 dd (10.2, 7.8)
  18          1.00 s                      1.03 s                      1.00 s                 1.02 s
  19          0.96 s                      0.96 s                      0.95 s                 0.95 s
  20          2.21 m                      2.35 m                      2.19 overlap           2.31 ddd (10.2, 9.6, 3.6)
  21          4.78 d (4.2)                4.84 d (3.6)                4.76 d (4.8)           4.80 d (3.6)
  22α         1.87 m                      1.89 dd (12.6, 10.8)        1.89 overlap           1.87 m
  22β         1.70 m                      1.35 dd (12.6, 5.4)         1.86 dd (12.0, 7.8)    1.79 overlap
  23          4.23 ddd (9.0, 6.6, 4.8)    4.08 ddd (10.8, 6.0, 5.4)   4.43 t (7.8)           4.25 dd (10.2, 4.2)
  24          3.83 d (4.8)                3.92 d (6.0)                3.17 s                 3.24 s
  26          1.78 s                      1.78 s                      1.27 s                 1.27s
  27          5.05 s                      5.00 s                      1.26 s                 1.26 s
  27          4.93 s                      4.91 s                                             
  28          1.78 s                      1.78 s                      1.78 s                 1.77 s
  29          4.85 s                      4.85 s                      4.84 s                 4.84 s
  29          5.02 s                      5.02 s                      5.02 s                 5.01 s
  30          1.14 s                      1.14 s                      1.14 s                 1.13 s
  1-OAc       2.04 s                      2.04 s                      2.04 s                 2.03 s
  7-OAc       1.96 s                      1.96 s                      1.96 s                 1.95 s
  3-OCH~3~    3.66 s                      3.66 s                      3.65 s                 3.65 s
  21-OCH~3~   3.39 s                      3.41 s                      3.38 s                 3.39 s

^a^ Chemical shifts are in ppm; *J* values in Hz are in parentheses; Measured in CDCl~3~.
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###### 

^13^C-NMR spectroscopic data (100 MHz) of compounds **1**--**4** ^a^.

  Position    1             2             3             4
  ----------- ------------- ------------- ------------- -------------
  1           77.2 CH       76.9 CH       76.8 CH       76.9 CH
  2           35.5 CH~2~    35.5 CH~2~    35.5 CH~2~    34.9 CH~2~
  3           172.0 C       172.1 C       172.0 C       172.1 C
  4           145.1 C       145.0 C       145.1 C       145.0 C
  5           44.3 CH       44.3 CH       44.3 CH       44.3 CH
  6           29.3 CH~2~    29.3 CH~2~    29.3 CH~2~    29.3 CH~2~
  7           74.7 CH       74.6 CH       74.7 CH       74.6 CH
  8           42.5 C        42.5 C        42.4 C        42.4 C
  9           34.5 CH       34.5 CH       34.4 CH       34.0 CH
  10          44.3 C        44.3 C        44.3 C        44.3 C
  11          18.5 CH~2~    18.4 CH~2~    18.5 CH~2~    18.4 CH~2~
  12          33.5 CH~2~    33.7 CH~2~    33.5 CH~2~    33.4 CH~2~
  13          46.3 C        46.6 C        46.2 C        46.6 C
  14          159.2 C       159.5 C       159.1 C       159.4 C
  15          119.1 CH      118.7 CH      119.2 CH      118.7 CH
  16          35.2 CH~2~    35.0 CH~2~    35.2 CH~2~    34.4 CH~2~
  17          52.9 CH       58.1 CH       52.7 CH       57.9 CH
  18          20.8 CH~3~    20.2 CH~3~    20.8 CH~3~    20.2 CH~3~
  19          15.2 CH~3~    15.2 CH~3~    15.2 CH~3~    15.2 CH~3~
  20          45.8 CH       47.0 CH       45.0 CH       46.1 CH
  21          104.6 CH      109.3 CH      104.9 CH      109.7 CH
  22          31.0 CH~2~    34.2 CH~2~    31.6 CH~2~    33.6 CH~2~
  23          80.7 CH       79.0 CH       79.0 CH       76.9 CH
  24          78.1 CH       78.4 CH       76.8 CH       75.7 CH
  25          144.9 C       144.6 C       73.1 C        73.3 C
  26          18.7 CH~3~    18.4 CH~3~    26.6 CH~3~    26.6 CH~3~
  27          112.8 CH~2~   113.6 CH~2~   26.5 CH~3~    26.5 CH~3~
  28          23.0 CH~3~    23.0 CH~3~    23.0 CH~3~    23.0 CH~3~
  29          116.6 CH~2~   116.6 CH~2~   116.6 CH~2~   116.6 CH~2~
  30          26.9 CH~3~    26.9 CH~3~    26.9 CH~3~    26.9 CH~3~
  1-OAc       170.5 C       170.5 C       170.5 C       170.5 C
              21.2 CH~3~    21.2 CH~3~    21.2 CH~3~    21.2 CH~3~
  7-OAc       170.2 C       170.2 C       170.2 C       170.2 C
              21.5 CH~2~    21.5 CH~2~    21.5 CH~2~    21.4 CH~2~
  3-OCH~3~    52.3 CH~3~    52.3 CH~3~    52.2 CH~3~    52.3 CH~3~
  21-OCH~3~   54.9 CH~3~    55.7 CH~3~    55.4 CH~3~    55.9 CH~3~

^a^ Assignments were made using HMQC and HMBC techniques; Measured in CDCl~3~.
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###### 

Cytotoxic activities of compounds **1**--**11** ^a^.

  Compound    ED~50~ (μg/mL)                                 
  ----------- ---------------- -------------- -------------- --------------
  **1**       28.12 ± 0.60     16.02 ± 0.41   33.56 ± 0.92   \>40
  **2**       36.05 ± 2.78     24.86 ± 1.70   \>40           \>40
  **3**       37.78 ± 0.43     30.34 ± 0.51   \>40           \>40
  **4**       37.72 ± 0.94     \>40           \>40           \>40
  **5**       11.38 ± 0.98     26.72 ± 1.01   15.49 ± 0.76   6.83 ± 0.63
  **6**       \>40             \>40           \>40           33.78 ± 1.66
  **7**       \>40             \>40           \>40           37.49 ± 1.98
  **8**       31.06 ± 2.89     \>40           \>40           \>40
  **9**       36.69 ± 2.30     34.36 ± 3.43   \> 40          \>40
  **10**      16.77 ± 2.36     \>40           \>40           \>40
  **11**      \>40             \>40           \>40           \>40
  mitomycin   0.16± 0.01       0.19± 0.01     0.19± 0.01     0.18± 0.01

^a^ Results are presented as mean ± S.E.M. (*n* = 3).
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###### 

Anti-inflammatory data of compounds **1**--**11** ^a^.

  Compound   Superoxide Anion   Elastase Release                 
  ---------- ------------------ ------------------ ------------- --------------
  **1**      \>10               41.94 ± 2.39       \>10          41.72 ± 4.47
  **2**      \>10               43.00 ± 4.46       \>10          44.83 ± 5.06
  **3**      \>10               33.20 ± 6.23       \>10          16.54 ± 3.36
  **4**      5.79 ± 0.88        74.39 ± 2.90       5.22 ± 0.24   78.36 ± 5.74
  **5**      1.25 ± 0.17        86.65 ± 1.75       2.26 ± 0.05   78.19 ± 0.56
  **6**      \>10               18.40 ± 0.84       \>10          7.93 ± 3.27
  **7**      \>10               13.71 ± 3.60       \>10          18.85 ± 2.47
  **8**      \>10               45.60 ± 3.63       \>10          21.39 ± 3.77
  **9**      \>10               43.92 ± 7.10       \>10          8.49 ± 1.05
  **10**     \>10               49.20 ± 2.20       \>10          39.36 ± 4.48
  **11**     \>10               44.85 ± 1.63       \>10          33.64 ± 8.34

^a^ Results are presented as mean ± S.E.M. (*n* = 3); ^b^ Concentration necessary for 50% inhibition (IC~50~); ^c^ Percentage of inhibition (Inh %) at 10 μg/mL concentration.
